<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298619</url>
  </required_header>
  <id_info>
    <org_study_id>HEM-FEDII-HL follow-up -001</org_study_id>
    <nct_id>NCT04298619</nct_id>
  </id_info>
  <brief_title>Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission</brief_title>
  <acronym>HOLYFU</acronym>
  <official_title>Impact on Survival of Early Detection of Recurrence in the Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cohort study enrolled high-risk Hodgkin Lymphoma patients in first relapse after induction
      therapy followed after remission either with a systemic imaging-based surveillance (Imaging
      cohort) or with standard clinical-based surveillance (standard cohort).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2001</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>Time period from the first relapse after induction therapy to the date of an event (refractoriness, relapse, or death) or the last follow-up visit after autologous stem cell transplantation (ASCT), up to 2 years</time_frame>
    <description>Events:
refractoriness
relapse
death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EFS for clinically silent relapses</measure>
    <time_frame>Time period from the first relapse after induction therapy to the date of an event (refractoriness, relapse, or death) or the last follow-up visit after autologous stem cell transplantation (ASCT), up to 2 years</time_frame>
    <description>Events:
refractoriness
relapse
death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>After salvage therapy and autologous stem cell transplantation (ASCT), up to 2 years</time_frame>
    <description>Rate of response</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">123</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>High Risk</condition>
  <condition>Relapse</condition>
  <arm_group>
    <arm_group_label>Standard cohort</arm_group_label>
    <description>Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients:
symptom assessment
blood tests
physical examination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imaging cohort</arm_group_label>
    <description>Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients:
symptom assessment
blood tests
physical examination
Positron Emission Tomography (PET)/Computed Tomography (CT) or Chest X-Ray ultrasonography scan of superficial, mediastinal, abdominal and pelvic lymph nodes</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Standard cohort: Clinical lab follow-up</intervention_name>
    <arm_group_label>Imaging cohort</arm_group_label>
    <arm_group_label>Standard cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Imaging cohort: integrated imaging follow-up</intervention_name>
    <arm_group_label>Imaging cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Standard cohort: patients followed-up at the Santa Maria Loreto Mare Hospital Imaging
        cohort: patients followed-up at the University of Naples Federico II
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High risk Hodgkin Lymphoma

          -  achievement of complete response to first line therapy

        Exclusion Criteria:

          -  comorbidities that could impair participation in follow-up procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Marco Picardi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

